Requested symbol wasn't found

U.S. Markets open in 6 hrs 46 mins


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire6 months ago

    WuXi Biologics Completes Construction of Asia's Largest Perfusion Biologics Manufacturing Facility Using Disposable Bioreactors

    SHANGHAI and WUXI, China, Sept. 22, 2016 /PRNewswire/ -- WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today the opening of a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China. In April 2015 WuXi Biologics announced plans to build a $150 million commercial biologics manufacturing facility in Wuxi city. This added capacity will support WuXi's robust biologics commercial manufacturing pipeline and enable WuXi to maintain its position as the premier biologics manufacturer in China as well as a leader worldwide.

  • PR Newswire11 months ago

    LabNetwork Forges eCommerce Alliances with Leading Chemical Providers

    SHANGHAI, April 27, 2016 /PRNewswire/ -- LabNetwork, a WuXi AppTec company, held a formal signing ceremony in Shanghai announcing strategic cooperation agreements with 8 top-ranking global chemical providers. With the vision of connecting suppliers and buyers on LabNetwork's global platform for research products, the agreements aim to explore development and speed the time to market of innovative and high quality research compounds.

  • Zackslast year

    AstraZeneca Invests in China, To Buy Respiratory Business

    AstraZeneca (AZN) expands its footprints in China; set to buy respiratory business from Takeda.